FDA Grants Priority Review For ARIXTRA(R) (fondaparinux Sodium) In The Treatment Of Acute Coronary Syndromes
Tue, 03 Oct 2006 07:00 AM EST
... GlaxoSmithKline plc (NYSE: GSK; London) announced today that the supplemental new drug application for its anticoagulant product ARIXTRA(R) (fondaparinux sodium) Injection has been accepted for priority review by the United States Food and Drug Administration. [click link for full article] ...
Related Topics
- Fondaparinux Sodium
- Acute Coronary Syndrome
- Coronary Artery Disease
- Coronary Artery Diseases
- Coronary Heart Disease
- Coronary Disease
- Sodium
- Coronary Angioplasty
- Sodium Bicarbonate
- Acute Care
- Sodium Flouride
- Otitis Media
- Atherosclerosis
- Coronary Occlusion
- Angioplasty
- Conjunctivitis
- Leukemia
- Coronary Artery Bypass Graft
- Sodium Azide
- Disease Prevention

Not Signed In -


